Reviewed by Peptide Treatments Medical Advisory Board
MK-677: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for MK-677.
Back to MK-677 overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (7 items)
| # | Side Effect |
|---|---|
| 1 | Increased appetite (40-50%) |
| 2 | Weight gain (20-30%) |
| 3 | Fatigue (10-15%) |
| 4 | Headache (~10%) |
| 5 | Muscle pain (5-10%) |
| 6 | Transient insulin resistance (5-10%) |
| 7 | Mild edema |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| Insulin / oral hypoglycemics | Documented | MK-677 increases fasting glucose and insulin resistance — dose adjustments needed |
| Somatostatin analogs (octreotide) | Documented | Somatostatin suppresses GH release, opposing MK-677 effect — separate by 4+ hours |